家庭眼压远程监测对眼压控制和青光眼进展的影响
家庭眼压远程监测对眼压控制和青光眼进展的影响 - 随机对照试验
该临床试验的目标是进行一项研究,将青光眼患者随机分配到家庭眼压远程监测结合基于智能手机的干预(管理范式 I)或单独基于智能手机的干预(管理范式 II),目的是比较(1 ) 整个研究期间的 GAT IOP 测量(主要结果测量)和 (2) 两种管理范式之间的视网膜神经纤维层 (RNFL) 变薄率(次要结果测量)。 我们假设,与随机分配到管理范式 I 的青光眼患者相比,随机分配到管理范式 I 的青光眼患者将 (1) 获得较低的 IOP 水平,以及 (2) 视网膜神经纤维层 (RNFL) 和神经节细胞内丛状层 (GCIPL) 变薄的速度较慢。管理范式 II 因为对 IOP 进行更精确的评估来指导降低 IOP 的治疗在管理范式 I 中是可行的。
其目的是:
比较两种管理范式之间的 (1) 整个研究期间的 GAT IOP 测量值(主要结果测量)和 (2) RNFL 稀疏率(次要结果测量)。
参与者将被要求做,
- 管理范式 I:将提供 iCare Home 并指示每周测量和上传 6 次 IOP 测量值(每周 2 天,清晨(上午 5 点至上午 9 点)测量 1 次,中午(中午 12 点)测量 1 次到下午 4 点)和晚上 1 点(晚上 7 点到晚上 11 点))通过 iCare CLINIC 发送到安全服务器(每周 IOP 测量次数遵循 HyperLink 研究中每周血压测量次数)。 早上的测量将包括两个读数,第一个读数是在起床前在仰卧位时获得的,第二个读数是在起床后立即在直立位时获得的。 如果患者从睡眠中醒来并在床上醒来,则可以在仰卧位以及一天中的其他时间进行额外的眼压测量,但这不是强制性的。 研究期间的治疗决策将不包括这些额外的眼压测量。
- 管理范例 II:在基线 IOP 测量后,患者将接受局部前列腺素类似物治疗。
研究概览
地位
详细说明
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Christopher Leung
- 电话号码:39102673
- 邮箱:cleung21@hku.hk
研究联系人备份
- 姓名:Anita Yau
- 电话号码:39102673
- 邮箱:anitayky@hku.hk
学习地点
-
-
-
Wong Chuk Hang、香港
- 招聘中
- HKU Eye Centre
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
纳入标准:
- 新诊断的原发性开角型青光眼 (POAG)
- 所含眼睛的最佳矫正视力 (VA) ≥20/40
排除标准:
- 眼压>35毫米汞柱
- 干眼症
- 中央角膜厚度 <500μm 或 >600μm
- 基线访视时未能完成 iCare Home 认证程序
- 只有一只眼睛具有功能性视力
- 无法执行可靠的 VF
- 病理性近视(眼轴≥26mm,有漆层裂纹、脉络膜视网膜萎缩)
- OCT 图像质量欠佳(RNFL 成像中如下所述)
- 既往做过眼内手术或角膜屈光手术(不包括简单的白内障摘除术)
- 糖尿病视网膜病变/黄斑病变
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Management Paradigm I: Home IOP telemonitoring with smart phone-based intervention
Before treatment initiation, patients perform 4 weeks of baseline home IOP measurements, then continue to obtain at least six IOP measurements per week (two readings in the early morning, and one each at mid-day and evening on two days per week) and upload readings via the iCare CLINIC cloud platform. Investigators review home IOP data every 4 weeks and adjust topical IOP-lowering therapy according to a predefined algorithm whenever fewer than 75% of home readings are below the target IOP based on disease severity. Every 4 weeks, patients receive smartphone text messages indicating whether the home-based target IOP has been achieved and reminding them about eye-drop adherence; patients report missed doses by text, and a nurse calls patients who do not reply or who submit fewer than 20 home IOP readings in 4 weeks. |
Participants use the iCare HOME rebound tonometer to perform self-measurements of intraocular pressure at home for 30 months. After a 4-week baseline period with at least 24 measurements (early morning supine and sitting, mid-day, and evening on different days), patients continue to obtain at least six IOP measurements per week and upload readings to the secure iCare CLINIC cloud system. Investigators review home IOP profiles every 4 weeks and use a predefined algorithm to determine whether treatment goals are met and whether glaucoma therapy should be intensified. |
|
有源比较器:Management paradigm II: Standard care and smart phone-based intervention
Topical IOP-lowering therapy is escalated according to the same predefined stepwise protocol used in Management Paradigm I when target IOP is not reached. No home IOP telemonitoring is used; treatment decisions rely on clinic-measured IOP and structural/functional assessments. Every 4 weeks, patients receive smartphone text messages indicating whether the target pressure has been attained based on the latest clinic Goldmann measurement and reminding them about eye-drop adherence; patients report missed doses by text, and clinic staff follow up by phone as needed. |
Every 4 weeks, participants receive automated or investigator-generated smartphone text messages summarizing whether their individualized target intraocular pressure has been achieved and reminding them to adhere to prescribed eye-drop therapy.
In Management Paradigm I, the feedback is based on home IOP readings from the iCare HOME device, whereas in Management Paradigm II it is based on the most recent clinic Goldmann applanation measurement.
Participants reply by text with the number of missed eye-drop doses over the past 4 weeks, and clinic staff contact patients by telephone when replies or monitoring data are insufficient.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
IOP levels over the study period
大体时间:From baseline to 30 months
|
From baseline to 30 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Rates of change of global, superotemporal and inferotemporal RNFL thicknesses.
大体时间:From baseline to 30 months
|
From baseline to 30 months
|
|
|
Rates of change of average and regional GCIPL thicknesses
大体时间:From baseline to 30 months
|
From baseline to 30 months
|
|
|
Visual field progression
大体时间:From baseline to 30 months
|
Visual field progression defined with reference to the EMGT criteria
|
From baseline to 30 months
|
其他结果措施
结果测量 |
大体时间 |
|---|---|
|
Number of IOP-lowering medications
大体时间:From baseline to 30 months
|
From baseline to 30 months
|
|
Agreement of IOP measurements between GAT and iCare
大体时间:From baseline to 30 months
|
From baseline to 30 months
|
合作者和调查者
合作者
调查人员
- 首席研究员:Christopher Leung、The University of Hong Kong
出版物和有用的链接
一般刊物
- Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006 Mar;90(3):262-7. doi: 10.1136/bjo.2005.081224.
- Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008 Jul;115(7):1123-1129.e3. doi: 10.1016/j.ophtha.2007.10.031. Epub 2008 Feb 20.
- Liu JH, Kripke DF, Twa MD, Hoffman RE, Mansberger SL, Rex KM, Girkin CA, Weinreb RN. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci. 1999 Nov;40(12):2912-7.
- Margolis KL, Asche SE, Bergdall AR, Dehmer SP, Groen SE, Kadrmas HM, Kerby TJ, Klotzle KJ, Maciosek MV, Michels RD, O'Connor PJ, Pritchard RA, Sekenski JL, Sperl-Hillen JM, Trower NK. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013 Jul 3;310(1):46-56. doi: 10.1001/jama.2013.6549.
- Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002 Oct 9;288(14):1775-9. doi: 10.1001/jama.288.14.1775.
- Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeffe J, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Silvester A, Stevens GA, Tahhan N, Wong TY, Taylor HR; Vision Loss Expert Group of the Global Burden of Disease Study. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017 Dec;5(12):e1221-e1234. doi: 10.1016/S2214-109X(17)30393-5. Epub 2017 Oct 11.
- Barkana Y, Anis S, Liebmann J, Tello C, Ritch R. Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma. Arch Ophthalmol. 2006 Jun;124(6):793-7. doi: 10.1001/archopht.124.6.793.
- Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E; Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003 Jan;121(1):48-56. doi: 10.1001/archopht.121.1.48.
- Weinreb RN, Leung CK, Crowston JG, Medeiros FA, Friedman DS, Wiggs JL, Martin KR. Primary open-angle glaucoma. Nat Rev Dis Primers. 2016 Sep 22;2:16067. doi: 10.1038/nrdp.2016.67.
- Liu JH, Zhang X, Kripke DF, Weinreb RN. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1586-90. doi: 10.1167/iovs.02-0666.
- Liu JH, Sit AJ, Weinreb RN. Variation of 24-hour intraocular pressure in healthy individuals: right eye versus left eye. Ophthalmology. 2005 Oct;112(10):1670-5. doi: 10.1016/j.ophtha.2005.05.007.
- Bengtsson B, Leske MC, Hyman L, Heijl A; Early Manifest Glaucoma Trial Group. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007 Feb;114(2):205-9. doi: 10.1016/j.ophtha.2006.07.060. Epub 2006 Nov 13.
- Hughes E, Spry P, Diamond J. 24-hour monitoring of intraocular pressure in glaucoma management: a retrospective review. J Glaucoma. 2003 Jun;12(3):232-6. doi: 10.1097/00061198-200306000-00009.
- Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008 Nov;53 Suppl1:S57-68. doi: 10.1016/j.survophthal.2008.08.002.
- Meier-Gibbons F, Berlin MS, Toteberg-Harms M. Twenty-four hour intraocular pressure measurements and home tonometry. Curr Opin Ophthalmol. 2018 Mar;29(2):111-115. doi: 10.1097/ICU.0000000000000460.
- Xu SC, Gauthier AC, Liu J. The Application of a Contact Lens Sensor in Detecting 24-Hour Intraocular Pressure-Related Patterns. J Ophthalmol. 2016;2016:4727423. doi: 10.1155/2016/4727423. Epub 2016 Jul 25.
- Mudie LI, LaBarre S, Varadaraj V, Karakus S, Onnela J, Munoz B, Friedman DS. The Icare HOME (TA022) Study: Performance of an Intraocular Pressure Measuring Device for Self-Tonometry by Glaucoma Patients. Ophthalmology. 2016 Aug;123(8):1675-1684. doi: 10.1016/j.ophtha.2016.04.044. Epub 2016 Jun 9.
- Margolis KL, Asche SE, Dehmer SP, Bergdall AR, Green BB, Sperl-Hillen JM, Nyboer RA, Pawloski PA, Maciosek MV, Trower NK, O'Connor PJ. Long-term Outcomes of the Effects of Home Blood Pressure Telemonitoring and Pharmacist Management on Blood Pressure Among Adults With Uncontrolled Hypertension: Follow-up of a Cluster Randomized Clinical Trial. JAMA Netw Open. 2018 Sep 7;1(5):e181617. doi: 10.1001/jamanetworkopen.2018.1617.
- Yu M, Lin C, Weinreb RN, Lai G, Chiu V, Leung CK. Risk of Visual Field Progression in Glaucoma Patients with Progressive Retinal Nerve Fiber Layer Thinning: A 5-Year Prospective Study. Ophthalmology. 2016 Jun;123(6):1201-10. doi: 10.1016/j.ophtha.2016.02.017. Epub 2016 Mar 19.
- Lin C, Mak H, Yu M, Leung CK. Trend-Based Progression Analysis for Examination of the Topography of Rates of Retinal Nerve Fiber Layer Thinning in Glaucoma. JAMA Ophthalmol. 2017 Mar 1;135(3):189-195. doi: 10.1001/jamaophthalmol.2016.5111.
- Heijl A, Leske MC, Bengtsson B, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol Scand. 2003 Jun;81(3):286-93. doi: 10.1034/j.1600-0420.2003.00070.x.
- Tu XM, Kowalski J, Zhang J, Lynch KG, Crits-Christoph P. Power analyses for longitudinal trials and other clustered designs. Stat Med. 2004 Sep 30;23(18):2799-815. doi: 10.1002/sim.1869.
- Nakakura S, Asaoka R, Terao E, Nagata Y, Fukuma Y, Oogi S, Shiraishi M, Kiuchi Y. Evaluation of rebound tonometer iCare IC200 as compared with IcarePRO and Goldmann applanation tonometer in patients with glaucoma. Eye Vis (Lond). 2021 Jul 1;8(1):25. doi: 10.1186/s40662-021-00249-z.
- Badakere SV, Chary R, Choudhari NS, Rao HL, Garudadri C, Senthil S. Agreement of Intraocular Pressure Measurement of Icare ic200 with Goldmann Applanation Tonometer in Adult Eyes with Normal Cornea. Ophthalmol Glaucoma. 2021 May-Jun;4(3):238-243. doi: 10.1016/j.ogla.2021.04.002.
- Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara-Blanco A, Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, McNaught AI, Negi A, Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald RP, Xing W, Zeyen TG. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015 Apr 4;385(9975):1295-304. doi: 10.1016/S0140-6736(14)62111-5. Epub 2014 Dec 19.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- Protocol_iCare_v2_20230523
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.